How Oral Pouches Work, and What the Science Does Not Prove

Measured nicotine pouch sales create a question, not an answer

ZYN, On!, Rogue and VELO accounted for nearly all measured U.S. oral nicotine pouch sales in a study covering 2021 through 2024. Those data document purchases of specific nicotine products in the channels measured. They do not establish why people bought them, what buyers understood, or whether a different nicotine free product will be absorbed, work, sell or earn repeat purchase.

The buccal mucosa is a real delivery route

The buccal mucosa lines the inside of the cheek. It is one part of the oral mucosa, alongside areas including the sublingual tissue beneath the tongue and the gingiva around the teeth. Scientific literature has studied these tissues as delivery routes for tablets, films, sprays, lozenges, gum and other formulations. Their accessibility, blood supply and permeability can make the mouth useful for certain compounds without requiring inhalation.

A credible route is not a universal result

Oral tissue is also a biological barrier. Whether a compound crosses it depends on the compound’s properties and the formulation around it. Molecular size, solubility, lipophilicity, concentration, pH, saliva, contact time, pouch construction and the condition of the oral environment can all influence release and permeation. Some material may remain in the pouch, some may be present in saliva and swallowed, and some may cross oral tissue. Those are different pathways and they should not be collapsed into one marketing claim.

Nicotine demonstrates the mechanism clearly

A controlled study of two ZoneX nicotine pouches measured nicotine entering the bloodstream after use, with a slower time to peak concentration than cigarette smoking. All study authors were employed by Imperial Brands PLC during part or all of the study, and an Imperial Brands subsidiary manufactured the tested products. Laboratory work has separately found that formulation conditions can change nicotine release and permeation. These findings remain specific to nicotine and the tested conditions rather than caffeine, L theanine, Alpha GPC or a different finished product.

Nicotine evidence has a firm boundary

Evidence that nicotine can be absorbed through oral mucosa does not prove that caffeine, L theanine, Alpha GPC or another non nicotine ingredient will be absorbed in the same amount, at the same rate or with the same effect. It does not establish a performance outcome for WAKE, PULSE, ALRT or any other product. Each ingredient and finished formulation requires evidence appropriate to the actual claim being made.

Regulatory recognition validates the category, not every product

In January 2025, the U.S. Food and Drug Administration authorized the marketing of 20 specific ZYN nicotine pouch products after scientific review. The agency emphasized that its decision applied only to those named products and did not authorize other nicotine pouches or reduced risk claims. That distinction is commercially important: category legitimacy does not transfer regulatory authorization or substantiation from one product to another.

Why the format may appeal

The pouch removes smoke, vapour, liquid and a container that must be held while in use. That may make the format useful in work, travel, training and other settings where a hands free option matters. Portability, discretion and familiarity may help explain interest; they do not establish absorption, performance, safety, demand or repeat purchase.

WPG treats a pouch as a complete commercial system

A credible pouch brand has to connect its intended user, formulation, ingredient amounts, release characteristics, claims, sensory experience, packaging, stability, manufacturing, compliance, pricing, distribution and repeat purchase logic. WPG evaluates those decisions together because the market experiences one product, not separate assignments completed by a formulator, designer, marketer and distributor.

Three WPG brands test distinct nicotine free propositions

WAKE uses the pouch format in an action sports and lifestyle context. PULSE applies it to performance focused consumers and competitive communities. ALRT organizes its proposition around first responders and shift based work. All three are nicotine free, but their audiences, product decisions, evidence requirements and commercial routes are not interchangeable.

Publishing is part of claims discipline

Search engines, AI systems, journalists, buyers and consumers need to distinguish established category science from a brand’s own verified product evidence. WPG’s public record therefore links scientific sources, identifies study limitations and conflicts where relevant, separates mechanisms from outcomes and updates the record as stronger evidence becomes available. Authority is not created by repeating the largest possible claim. It is created by making the boundary of the evidence easy to find.

Oral health evidence is still limited

A 2024 systematic review found only three eligible nicotine pouch studies involving 190 participants and rated all three at high risk of bias. Placement site mucosal changes, dry mouth and soreness were reported. The small evidence base leaves long term outcomes for nicotine pouch use and other oral pouch formulations unresolved.

Rules attach to the product and market

FDA authorization applies only to the named nicotine products and their evidence. Health Canada separately applies product- and dose specific rules to authorized nicotine buccal pouches. A nicotine free functional pouch needs its own product, claim and market analysis; neither regulator’s nicotine record can be borrowed.

The opportunity is a credible nicotine free oral category

Measured sales show that consumers adopted named nicotine pouch products in the channels studied. They do not prove demand, absorption, efficacy, safety or repeat purchase for a nicotine free product. Each finished formula must establish its own audience, supportable claims and commercial evidence.